CLARITY study: Expression data from RRMS patients treated with Oral Cladribine versus Placebo at week 96

The CLARITY trial (NCT00213135) was designed as a double-blind, placebo-controlled study to allow the best comparison of absolute efficacy and safety of oral cladribine in RRMS subjects. 1326 patients with relapsing MS were randomized (1:1:1) to receive cladribine tablets 3.5 mg/kg or 5.25 mg/kg bodyweight or placebo. Gene expression data in whole blood samples at 96 weeks were prepared according to standard Affymetrix protocols Gene expression data in whole blood samples at 96 weeks were available from patients randomized to placebo (n=57), cladribine tablets 3.5 mg/kg (n=62), and cladribine tablets 5.25 mg/kg (n=70). Transcriptome of the whole blood from RRMS patients either treated with high (5.25 mg/kg) or low dose (3.5 mg/kg) of cladribine or from placebo arm at 96 weeks after start day.